Literature DB >> 22160635

Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.

Samer Gawrieh1, Miranda C Marion, Richard Komorowski, James Wallace, Michael Charlton, Ahmed Kissebah, Carl D Langefeld, Michael Olivier.   

Abstract

BACKGROUND: The peroxisome proliferator activated receptor-gamma (PPARG) is a nuclear receptor that regulates adipocyte differentiation, insulin sensitivity and lipid metabolism, thus, it represents a good candidate gene for non-alcoholic fatty liver disease (NAFLD). PURPOSE AND
METHOD: We investigated the association of two PPARG variants (Pro12Ala and C1431T) with NAFLD and its histological features. DNA was extracted from 274 archived, formalin-fixed liver biopsy specimens from 212 patients with NAFLD and 62 controls with normal liver histology.
RESULTS: Individual SNPs did not show significant association with NAFLD or its histological features. A haplotype comprised of both minor alleles (GT) was less enriched whereas a haplotype comprised of the two major alleles (CC) was more enriched in subjects with NAFLD compared to controls [9.3% vs. 28.1% for GT (P = 0.001, OR 0.26 (range 0.14-0.48) and 80.4% vs. 64.8% for CC (P = 0.037, OR 2.23 (range 1.30-3.81)]. Both haplotypes were significantly associated with steatosis and fibrosis. The GT haplotype was also associated with lobular inflammation.
CONCLUSIONS: Genetic variation in PPARG is associated with NAFLD, and the GT haplotype is associated with inflammatory and fibrotic changes that denote histologically advanced NAFLD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160635     DOI: 10.1007/s10620-011-1994-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes.

Authors:  S Bernard; S Touzet; I Personne; V Lapras; P J Bondon; F Berthezène; P Moulin
Journal:  Diabetologia       Date:  2000-08       Impact factor: 10.122

2.  Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.

Authors:  Johannes-W Rey; Andrea Noetel; Aline Hardt; Ali Canbay; Hakan Alakus; Axel Zur Hausen; Hans-Peter Dienes; Uta Drebber; Margarete Odenthal
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

3.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 4.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

Review 5.  Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.

Authors:  Onpan Cheung; Arun J Sanyal
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

6.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

7.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

8.  A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.

Authors:  A Kotronen; L E Johansson; L M Johansson; C Roos; J Westerbacka; A Hamsten; R Bergholm; P Arkkila; J Arola; T Kiviluoto; R M Fisher; E Ehrenborg; M Orho-Melander; M Ridderstråle; L Groop; H Yki-Järvinen
Journal:  Diabetologia       Date:  2009-02-18       Impact factor: 10.122

9.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

Authors:  P Tontonoz; E Hu; B M Spiegelman
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

10.  Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study.

Authors:  Paola Dongiovanni; Raffaela Rametta; Anna Ludovica Fracanzani; Luca Benedan; Vittorio Borroni; Paolo Maggioni; Marco Maggioni; Silvia Fargion; Luca Valenti
Journal:  BMC Gastroenterol       Date:  2010-09-08       Impact factor: 3.067

View more
  19 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease.

Authors:  Chun Wang; Jianping Gong; Hao Wu
Journal:  Biomed Rep       Date:  2017-06-14

4.  Meta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Genet Test Mol Biomarkers       Date:  2014-04-03

5.  Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?

Authors:  Paola Dongiovanni; Luca Valenti
Journal:  PPAR Res       Date:  2013-02-04       Impact factor: 4.964

6.  PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.

Authors:  Marion Peyrou; Pierluigi Ramadori; Lucie Bourgoin; Michelangelo Foti
Journal:  PPAR Res       Date:  2012-09-13       Impact factor: 4.964

7.  Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.

Authors:  Kayleigh L Wood; Michael H Miller; John F Dillon
Journal:  BMJ Open Gastroenterol       Date:  2015-02-17

8.  Endogenously increased n-3 PUFA levels in fat-1 transgenic mice do not protect from non-alcoholic steatohepatitis.

Authors:  Marie Liebig; Dirk Dannenberger; Brigitte Vollmar; Kerstin Abshagen
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

9.  Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity.

Authors:  Luis A Videla; Paulina Pettinelli
Journal:  PPAR Res       Date:  2012-12-09       Impact factor: 4.964

10.  Update on pparγ and nonalcoholic Fatty liver disease.

Authors:  Gene P Ables
Journal:  PPAR Res       Date:  2012-08-16       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.